Pub Date : 2024-08-01DOI: 10.1001/jamadermatol.2024.1775
Sonia Himed, Hoda Tawfik, Benjamin H Kaffenberger
{"title":"Treatment of Pyoderma Gangrenosum With Vilobelimab.","authors":"Sonia Himed, Hoda Tawfik, Benjamin H Kaffenberger","doi":"10.1001/jamadermatol.2024.1775","DOIUrl":"10.1001/jamadermatol.2024.1775","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1001/jamadermatol.2024.1987
Meredith Tyree Polaskey, Christy H Chang, Karishma Daftary, Sheiva Fakhraie, Corinne H Miller, Raj Chovatiya
Importance: Seborrheic dermatitis is a prevalent chronic inflammatory skin disease, yet its global prevalence, pathogenesis, and epidemiology remain inadequately defined.
Objective: To provide a detailed estimation of the global prevalence of seborrheic dermatitis, analyze demographic variations, and explore differences in various settings.
Data sources: Embase, PubMed, Scopus, and Cochrane Database of Systematic Reviews were searched from inception through October 2023.
Study selection: Original investigations on seborrheic dermatitis prevalence were included after duplicate screening of titles, abstracts, and full articles, including only studies with clinician-diagnosed cases.
Data extraction and synthesis: Following PRISMA guidelines, data were extracted and quality was assessed independently by multiple reviewers. A random-effects model using restricted maximum likelihood was used for meta-analysis and subgroup analyses.
Main outcome and measure: The primary outcome was the pooled estimate of global seborrheic dermatitis prevalence.
Results: From 1574 identified articles, 121 studies were included, encompassing 1 260 163 individuals and revealing a pooled global seborrheic dermatitis prevalence of 4.38% (95% CI, 3.58%-5.17%), with significant heterogeneity (I2 = 99.94%). Subgroup analyses showed variations by age, with a higher prevalence in adults (5.64% [95% CI, 4.01%-7.27%]) compared to children (3.70% [95% CI, 2.69%-4.80%]) and neonates (0.23% [95% CI, 0.04%-0.43%]). Geographic analyses indicated variability, with the highest prevalence in South Africa (8.82% [95% CI, 3.00%-14.64%]) and the lowest in India (2.62% [95% CI, 1.33%-3.92%]).
Conclusions and relevance: This comprehensive meta-analysis provides a detailed estimation of the global prevalence of seborrheic dermatitis, highlighting significant variability across different demographics and settings.
{"title":"The Global Prevalence of Seborrheic Dermatitis: A Systematic Review and Meta-Analysis.","authors":"Meredith Tyree Polaskey, Christy H Chang, Karishma Daftary, Sheiva Fakhraie, Corinne H Miller, Raj Chovatiya","doi":"10.1001/jamadermatol.2024.1987","DOIUrl":"10.1001/jamadermatol.2024.1987","url":null,"abstract":"<p><strong>Importance: </strong>Seborrheic dermatitis is a prevalent chronic inflammatory skin disease, yet its global prevalence, pathogenesis, and epidemiology remain inadequately defined.</p><p><strong>Objective: </strong>To provide a detailed estimation of the global prevalence of seborrheic dermatitis, analyze demographic variations, and explore differences in various settings.</p><p><strong>Data sources: </strong>Embase, PubMed, Scopus, and Cochrane Database of Systematic Reviews were searched from inception through October 2023.</p><p><strong>Study selection: </strong>Original investigations on seborrheic dermatitis prevalence were included after duplicate screening of titles, abstracts, and full articles, including only studies with clinician-diagnosed cases.</p><p><strong>Data extraction and synthesis: </strong>Following PRISMA guidelines, data were extracted and quality was assessed independently by multiple reviewers. A random-effects model using restricted maximum likelihood was used for meta-analysis and subgroup analyses.</p><p><strong>Main outcome and measure: </strong>The primary outcome was the pooled estimate of global seborrheic dermatitis prevalence.</p><p><strong>Results: </strong>From 1574 identified articles, 121 studies were included, encompassing 1 260 163 individuals and revealing a pooled global seborrheic dermatitis prevalence of 4.38% (95% CI, 3.58%-5.17%), with significant heterogeneity (I2 = 99.94%). Subgroup analyses showed variations by age, with a higher prevalence in adults (5.64% [95% CI, 4.01%-7.27%]) compared to children (3.70% [95% CI, 2.69%-4.80%]) and neonates (0.23% [95% CI, 0.04%-0.43%]). Geographic analyses indicated variability, with the highest prevalence in South Africa (8.82% [95% CI, 3.00%-14.64%]) and the lowest in India (2.62% [95% CI, 1.33%-3.92%]).</p><p><strong>Conclusions and relevance: </strong>This comprehensive meta-analysis provides a detailed estimation of the global prevalence of seborrheic dermatitis, highlighting significant variability across different demographics and settings.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11223058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1001/jamadermatol.2024.1281
Zachary H Hopkins, Lourdes Maria Perez-Chada
{"title":"Validating Patient-Reported Outcome Measures in Dermatology.","authors":"Zachary H Hopkins, Lourdes Maria Perez-Chada","doi":"10.1001/jamadermatol.2024.1281","DOIUrl":"10.1001/jamadermatol.2024.1281","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141306021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-31DOI: 10.1001/jamadermatol.2024.2351
Cruz Riley, Rebecca Vasquez, Ellen N Pritchett
{"title":"Equipping Dermatologists to Address Structural and Social Drivers of Inequities-Structural Competency.","authors":"Cruz Riley, Rebecca Vasquez, Ellen N Pritchett","doi":"10.1001/jamadermatol.2024.2351","DOIUrl":"https://doi.org/10.1001/jamadermatol.2024.2351","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-31DOI: 10.1001/jamadermatol.2024.2463
Kilian Eyerich, Khusru Asadullah, Andreas Pinter, Peter Weisenseel, Kristian Reich, Carle Paul, Robert Sabat, Kerstin Wolk, Stefanie Eyerich, Felix Lauffer, Julianty Angsana, Friedemann J H Taut, Kristen Kohler, Yanqing Chen, Jocelyn Sendecki, Monica W L Leung, Sven Wegner, Yvonne Personke, Mario Gomez, Nenja Krüger, Sarah Tabori, Knut Schäkel
Importance: Psoriasis is a chronic inflammatory skin disease with unmet needs for tailored treatment and therapy de-escalation strategies.
Objective: To evaluate early intervention with and prolonging the dosing interval for guselkumab, a p19 subunit-targeted interleukin (IL)-23 inhibitor, in patients with moderate to severe psoriasis.
Design, setting, and participants: The GUIDE clinical trial is an ongoing phase 3b, randomized, double-blinded trial conducted across 80 centers in Germany and France comprising 3 parts evaluating the impact of early disease intervention, prolonged dosing interval, and maintenance of response following treatment withdrawal among adults with moderate to severe plaque psoriasis. In study part 2, reported herein, first and last patient visits were September 2019 and March 2022, respectively.
Interventions: In GUIDE part 1 (week [W]0-W28), patients received guselkumab, 100 mg, at W0, W4, W12, and W20. Those achieving a Psoriasis Area and Severity Index (PASI) of 0 at both W20 and W28 were termed super responders (SRes). In part 2 (W28-W68), SRes were randomized to guselkumab, 100 mg, every 8 weeks or every 16 weeks; non-SRes continued open-label guselkumab every 8 weeks.
Main outcomes and measures: Primary objective was to demonstrate noninferiority (with a 10% margin) of guselkumab every 16 weeks vs every 8 weeks dosing among SRes for maintenance of disease control (PASI <3 at W68). Biomarker substudies assessed immunologic effects in skin and blood.
Results: Overall, 822 patients received guselkumab in part 2 (297 [36.1%] SRes [every 8 weeks/every 16 weeks; n = 148/n = 149] and 525 [63.9%] non-SRes). Among SRes, mean (SD) age was 39.4 (14.1) years, 95 (32.0%) were female, and 202 (68.0%) were male. The primary end point of noninferiority for guselkumab every 16 weeks vs every 8 weeks in SRes was met (P = .001), with 91.9% (137/149; 90% CI, 87.3%-95.3%) of SRes receiving every 16 weeks and 92.6% (137/148; 90% CI, 88.0%-95.8%) of SRes receiving dosing every 8 weeks having PASI lower than 3 at W68. Clinical effects corresponded with immunologic changes; skin CD8-positive tissue-resident memory T (TRM)-cell count decreased quickly from baseline, remaining low in both dosing groups. Similarly, serum IL-17A, IL-17F, IL-22, and β defensin (BD)-2 levels decreased significantly from baseline, remaining low in both dosing groups to W68. Guselkumab was well-tolerated; no new safety signals were identified.
Conclusions and relevance: Psoriasis treatment guidelines lack or provide inconsistent advice on patient stratification and treatment de-escalation. We present the first randomized trial providing evidence that, in patients with early complete skin clearance at 2 consecutive visits (W20 and W28), extending the guselkumab dosing interval may control disease activity.
{"title":"Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.","authors":"Kilian Eyerich, Khusru Asadullah, Andreas Pinter, Peter Weisenseel, Kristian Reich, Carle Paul, Robert Sabat, Kerstin Wolk, Stefanie Eyerich, Felix Lauffer, Julianty Angsana, Friedemann J H Taut, Kristen Kohler, Yanqing Chen, Jocelyn Sendecki, Monica W L Leung, Sven Wegner, Yvonne Personke, Mario Gomez, Nenja Krüger, Sarah Tabori, Knut Schäkel","doi":"10.1001/jamadermatol.2024.2463","DOIUrl":"10.1001/jamadermatol.2024.2463","url":null,"abstract":"<p><strong>Importance: </strong>Psoriasis is a chronic inflammatory skin disease with unmet needs for tailored treatment and therapy de-escalation strategies.</p><p><strong>Objective: </strong>To evaluate early intervention with and prolonging the dosing interval for guselkumab, a p19 subunit-targeted interleukin (IL)-23 inhibitor, in patients with moderate to severe psoriasis.</p><p><strong>Design, setting, and participants: </strong>The GUIDE clinical trial is an ongoing phase 3b, randomized, double-blinded trial conducted across 80 centers in Germany and France comprising 3 parts evaluating the impact of early disease intervention, prolonged dosing interval, and maintenance of response following treatment withdrawal among adults with moderate to severe plaque psoriasis. In study part 2, reported herein, first and last patient visits were September 2019 and March 2022, respectively.</p><p><strong>Interventions: </strong>In GUIDE part 1 (week [W]0-W28), patients received guselkumab, 100 mg, at W0, W4, W12, and W20. Those achieving a Psoriasis Area and Severity Index (PASI) of 0 at both W20 and W28 were termed super responders (SRes). In part 2 (W28-W68), SRes were randomized to guselkumab, 100 mg, every 8 weeks or every 16 weeks; non-SRes continued open-label guselkumab every 8 weeks.</p><p><strong>Main outcomes and measures: </strong>Primary objective was to demonstrate noninferiority (with a 10% margin) of guselkumab every 16 weeks vs every 8 weeks dosing among SRes for maintenance of disease control (PASI <3 at W68). Biomarker substudies assessed immunologic effects in skin and blood.</p><p><strong>Results: </strong>Overall, 822 patients received guselkumab in part 2 (297 [36.1%] SRes [every 8 weeks/every 16 weeks; n = 148/n = 149] and 525 [63.9%] non-SRes). Among SRes, mean (SD) age was 39.4 (14.1) years, 95 (32.0%) were female, and 202 (68.0%) were male. The primary end point of noninferiority for guselkumab every 16 weeks vs every 8 weeks in SRes was met (P = .001), with 91.9% (137/149; 90% CI, 87.3%-95.3%) of SRes receiving every 16 weeks and 92.6% (137/148; 90% CI, 88.0%-95.8%) of SRes receiving dosing every 8 weeks having PASI lower than 3 at W68. Clinical effects corresponded with immunologic changes; skin CD8-positive tissue-resident memory T (TRM)-cell count decreased quickly from baseline, remaining low in both dosing groups. Similarly, serum IL-17A, IL-17F, IL-22, and β defensin (BD)-2 levels decreased significantly from baseline, remaining low in both dosing groups to W68. Guselkumab was well-tolerated; no new safety signals were identified.</p><p><strong>Conclusions and relevance: </strong>Psoriasis treatment guidelines lack or provide inconsistent advice on patient stratification and treatment de-escalation. We present the first randomized trial providing evidence that, in patients with early complete skin clearance at 2 consecutive visits (W20 and W28), extending the guselkumab dosing interval may control disease activity.</p><","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-31DOI: 10.1001/jamadermatol.2024.2404
Arash Mostaghimi, Ahmed M Soliman, Chao Li, Yazan K Barqawi, Ayman Grada
Importance: Alopecia areata (AA) has been associated with multiple comorbidities, yet information regarding the timing of comorbidity development after AA diagnosis is limited.
Objective: To evaluate the prevalence and new-onset incidence of psychiatric and autoimmune comorbidities in patients with AA in the US.
Design, setting, and participants: This retrospective cohort analysis used data collected from January 1, 2007, to April 30, 2023, from the Merative MarketScan Research Databases, which contains medical and drug claims data from more than 46 million patients in the US. Data from adolescent and adult patients (aged 12-64 years) diagnosed with AA and patients without AA (ie, controls) were evaluated. For some analyses, patients with AA were matched (1:4) to controls based on sex, age, and geographic region.
Main outcomes and measures: Prevalence (at the time of AA diagnosis) and incidence (new onset after AA diagnosis) of psychiatric and autoimmune diseases were reported as percentage of patients. Risk of developing a new-onset psychiatric or autoimmune disease after AA diagnosis was calculated as adjusted hazard ratios (AHRs) with 95% CIs.
Results: At baseline, 63 384 patients with AA and 3 309 107 without AA were identified. After matching, there were 16 512 and 66 048 patients in the AA and control groups, respectively, with a mean (SD) age of 36.9 (13.4) years and 50.6% of whom were female. Compared with the unmatched controls, patients with AA had higher prevalence of psychiatric (30.9% vs 26.8%; P < .001) and autoimmune (16.1% vs 8.9%; P < .0001) comorbidities at AA diagnosis; incidence was also higher in patients with AA (without history of these comorbidities) vs the matched control group. Patients with AA vs controls had a significantly higher risk of developing a psychiatric (AHR, 1.3; 95% CI, 1.3-1.4) or autoimmune (AHR, 2.7; 95% CI, 2.5-2.8) comorbidity.
Conclusions and relevance: In this cohort study, patients with AA had a higher prevalence of autoimmune and psychiatric comorbidities at AA diagnosis and demonstrated an elevated risk of new-onset autoimmune and psychiatric comorbidities after their diagnosis. These data highlight the most common comorbidities among patients with AA and may help physicians counsel and monitor patients newly diagnosed with AA.
重要性:斑秃(AA)与多种合并症有关,但有关确诊 AA 后合并症发生时间的信息却很有限:目的:评估美国 AA 患者中精神疾病和自身免疫合并症的患病率和新发病率:这项回顾性队列分析使用了从 2007 年 1 月 1 日至 2023 年 4 月 30 日从 Merative MarketScan 研究数据库收集的数据,该数据库包含美国 4600 多万患者的医疗和药物索赔数据。该数据库包含 4600 万名美国患者的医疗和药物索赔数据。我们对确诊为 AA 的青少年和成年患者(12-64 岁)以及无 AA 的患者(即对照组)的数据进行了评估。在某些分析中,AA 患者与对照组根据性别、年龄和地理区域进行了配对(1:4):精神疾病和自身免疫性疾病的患病率(确诊为 AA 时)和发病率(确诊为 AA 后新发病)以患者百分比的形式报告。确诊 AA 后新发精神病或自身免疫性疾病的风险以调整后的危险比(AHRs)和 95% CIs 计算:基线时,共发现 63 384 名 AA 患者和 3 309 107 名非 AA 患者。配对后,AA 组和对照组分别有 16 512 名和 66 048 名患者,平均(标清)年龄为 36.9(13.4)岁,其中 50.6% 为女性。与未配对的对照组相比,AA 患者的精神病患病率更高(30.9% 对 26.8%;P 结论及意义:在这项队列研究中,AA 患者在确诊为 AA 时患有自身免疫性疾病和精神疾病的比例较高,确诊后新发自身免疫性疾病和精神疾病的风险也较高。这些数据强调了 AA 患者最常见的合并症,可帮助医生对新诊断为 AA 的患者进行咨询和监测。
{"title":"Immune-Mediated and Psychiatric Comorbidities Among Patients Newly Diagnosed With Alopecia Areata.","authors":"Arash Mostaghimi, Ahmed M Soliman, Chao Li, Yazan K Barqawi, Ayman Grada","doi":"10.1001/jamadermatol.2024.2404","DOIUrl":"10.1001/jamadermatol.2024.2404","url":null,"abstract":"<p><strong>Importance: </strong>Alopecia areata (AA) has been associated with multiple comorbidities, yet information regarding the timing of comorbidity development after AA diagnosis is limited.</p><p><strong>Objective: </strong>To evaluate the prevalence and new-onset incidence of psychiatric and autoimmune comorbidities in patients with AA in the US.</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort analysis used data collected from January 1, 2007, to April 30, 2023, from the Merative MarketScan Research Databases, which contains medical and drug claims data from more than 46 million patients in the US. Data from adolescent and adult patients (aged 12-64 years) diagnosed with AA and patients without AA (ie, controls) were evaluated. For some analyses, patients with AA were matched (1:4) to controls based on sex, age, and geographic region.</p><p><strong>Main outcomes and measures: </strong>Prevalence (at the time of AA diagnosis) and incidence (new onset after AA diagnosis) of psychiatric and autoimmune diseases were reported as percentage of patients. Risk of developing a new-onset psychiatric or autoimmune disease after AA diagnosis was calculated as adjusted hazard ratios (AHRs) with 95% CIs.</p><p><strong>Results: </strong>At baseline, 63 384 patients with AA and 3 309 107 without AA were identified. After matching, there were 16 512 and 66 048 patients in the AA and control groups, respectively, with a mean (SD) age of 36.9 (13.4) years and 50.6% of whom were female. Compared with the unmatched controls, patients with AA had higher prevalence of psychiatric (30.9% vs 26.8%; P < .001) and autoimmune (16.1% vs 8.9%; P < .0001) comorbidities at AA diagnosis; incidence was also higher in patients with AA (without history of these comorbidities) vs the matched control group. Patients with AA vs controls had a significantly higher risk of developing a psychiatric (AHR, 1.3; 95% CI, 1.3-1.4) or autoimmune (AHR, 2.7; 95% CI, 2.5-2.8) comorbidity.</p><p><strong>Conclusions and relevance: </strong>In this cohort study, patients with AA had a higher prevalence of autoimmune and psychiatric comorbidities at AA diagnosis and demonstrated an elevated risk of new-onset autoimmune and psychiatric comorbidities after their diagnosis. These data highlight the most common comorbidities among patients with AA and may help physicians counsel and monitor patients newly diagnosed with AA.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-31DOI: 10.1001/jamadermatol.2024.2378
Axel De Greef, Caroline Peeters, Olivier Dewit, Laurence de Montjoye, Marie Baeck
{"title":"Upadacitinib for Treatment of Granulomatous Cheilitis.","authors":"Axel De Greef, Caroline Peeters, Olivier Dewit, Laurence de Montjoye, Marie Baeck","doi":"10.1001/jamadermatol.2024.2378","DOIUrl":"10.1001/jamadermatol.2024.2378","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-31DOI: 10.1001/jamadermatol.2024.2462
Andrew Blauvelt, Curdin Conrad, Megan H Noe
{"title":"Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis.","authors":"Andrew Blauvelt, Curdin Conrad, Megan H Noe","doi":"10.1001/jamadermatol.2024.2462","DOIUrl":"https://doi.org/10.1001/jamadermatol.2024.2462","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}